Common Stock, par value $0.007 per share
- Symbol
- BIAF
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
bioAffinity Technologies, Inc.
BIAFNASDAQEQUITYCurrent
Other Events
Item 8.01. Other Events. On July 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of the Company’s next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with…
Company context
bioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath ® Lung, is a non-invasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
Current securities
Registered securities in this filing
bioAffinity Technologies, Inc. · 8-K · Filed 2026-07-22
Warrants to purchase Common Stock
- Symbol
- BIAFW
- Exchange
- NASDAQ
- Classification
- WARRANT
- Status
- Current
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item
8.01. Other Events.
On
July 22, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing
a collaboration with Pictor, Inc., a targeted proteomic platform company, to support development and commercialization of the Company’s
next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic
obstructive pulmonary disease (COPD).
A
copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Filed exhibits (1)
EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD Collaboration increases laboratory throughput and reduces costs for personalized testing for asthma and COPD, which affect more than 40 million Americans and 650 million people worldwide Global asthma and COPD therapeutics market projected to exceed $108 billion in 2026 and $155 billion by 2030, driven by increasing use of targeted therapies and biologics Tests under development are intended to help match asthma and COPD patients with more effective and personalized treatments targeting their specific inflammatory profile SAN ANTONIO, Texas - July 22, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics and targeted therapeutics, today announced a collaboration with Pictor®, Inc., a targeted proteomic platform company, to support development and commercialization of bioAffinity Technologies’ next-generation diagnostic tests designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive p…
Open exhibit ↗